Curaleaf Holdings (CURLF) Non-Current Deffered Revenue (2023 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Non-Current Deffered Revenue of $2.0 million for Q4 2024, down 90.61% year-over-year from $21.3 million in Q1 2024, and down 91.58% quarter-over-quarter from $23.7 million in Q3 2024.
Curaleaf Holdings (CURLF) Non-Current Deffered Revenue (2023 - 2026) Analysis & Trends
Curaleaf Holdings' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $2.0 million for Q4 2024.
- In Q4 2024, Non-Current Deffered Revenue fell 90.61% year-over-year to $2.0 million; the TTM figure through Dec 2024 stood at $2.0 million (down 90.61% YoY), while the FY2024 annual figure was $2.0 million, down 90.61% from the prior year.
- Non-Current Deffered Revenue for Q4 2024 stood at $2.0 million, down from $23.7 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $40.2 million in Q2 2023, with the low at $2.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn | 125,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125,000.00 |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | 23.75 Mn |
| Jun 30, 2024 | 22.93 Mn |
| Dec 31, 2023 | 21.31 Mn |
| Sep 30, 2023 | 40.22 Mn |
| Jun 30, 2023 | 40.22 Mn |